[SCHEDULE 13D/A] Aspira Women's Health Inc. SEC Filing

Rhea-AI Filing Summary

Aspira Women's Health Inc. reporting persons Jack W. Schuler and the Jack W. Schuler Living Trust amended their Schedule 13D to disclose transactions that increase their ownership to 3,830,365 shares, representing 9.1% of the outstanding common stock based on a post-transaction share count of 42,205,918. The Trust purchased 1,111,111 shares and received a warrant to buy 833,333 shares under a September 2025 Purchase Agreement. The September 2025 Warrant is exercisable at $0.75 per share for five years. Mr. Schuler is sole trustee and the Trust holds shared voting and dispositive power over 3,823,829 shares.

Positive

• Increase in disclosed ownership to 9.1%, providing transparency on significant holder position
• Acquisition included warrants exercisable at $0.75, potentially aligning holder interest with future upside

Negative

• No change-in-control or strategic plan disclosed; purchase appears financial rather than operational
• Exercise price low relative to current share count could suggest dilution risk to other holders if exercised (warrant covers 833,333 shares)

Insights

Securities Analyst

TL;DR: The filing discloses a meaningful equity purchase and attached warrants raising a holder to 9.1% ownership.

The amendment clarifies the source and size of the Trust's position: a direct purchase of 1,111,111 shares plus an 833,333-share warrant exercisable at $0.75 for five years. The filing restates holdings and voting/dispositive allocations and calculates ownership using an adjusted outstanding share count of 42,205,918. No other transactions in the prior 60 days are reported. This is a transactional ownership disclosure rather than a change in control proposal or disclosed strategic arrangement.

Corporate Governance Expert

TL;DR: Governance note — Mr. Schuler controls the Trust and retains shared voting power over the disclosed stake.

The amendment confirms that Jack W. Schuler is the sole trustee and that the Trust holds shared voting and dispositive power over 3,823,829 shares, which is the material governance fact in this filing. The document also incorporates forms of the purchase agreement and warrant as exhibits, indicating contractual documentation is filed with the amendment. No litigation disclosures or additional arrangements are reported in this amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 18)

Aspira Women's Health Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

04537Y208

(CUSIP Number)

Jack W. Schuler
PO Box 531,
Lake Bluff, IL, 60044
(520) 906-2991

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/17/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 04537Y208

1

Name of reporting person

SCHULER JACK W

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,536.00
8	Shared Voting Power 3,823,829.00
9	Sole Dispositive Power 6,536.00
10	Shared Dispositive Power 3,823,829.00

11

Aggregate amount beneficially owned by each reporting person

3,830,365.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 04537Y208

1

Name of reporting person

Jack W. Schuler Living Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ILLINOIS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,823,829.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,823,829.00

11

Aggregate amount beneficially owned by each reporting person

3,823,829.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.001 par value
(b)	Name of Issuer: Aspira Women's Health Inc.
(c)	Address of Issuer's Principal Executive Offices: 12117 BEE CAVES ROAD BUILDING THREE, Suite 100, Austin, TEXAS , 78738.
Item 4.	Purpose of Transaction
	This Amendment No. 18 to Schedule 13D (this "Amendment") hereby amends and supplements Item 4 by adding the following thereto: "The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4. On September 17, 2025, the Trust purchased from the Issuer the Common Stock and September 2025 Warrants pursuant to the September 2025 Purchase Agreement (in each case as defined and further described in Item 6 below)."
Item 5.	Interest in Securities of the Issuer
(a)	This Amendment hereby amends and restates Item 5(a) in its entirety as follows: "The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 35,655,918 Shares outstanding as of August 8, 2025, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2025 plus the 6,550,000 shares of Common Stock sold pursuant to the September 2025 Purchase Agreement for a total of 42,205,918 Shares outstanding."
(b)	This Amendment hereby amends and restates Item 5(b) in its entirety as follows: "The information set forth in Rows 7 through 13 of the cover page hereto for each of Mr. Schuler and the Trust is incorporated herein by reference."
(c)	This Amendment hereby amends and restates Item 5(c) in its entirety as follows: "Neither Mr. Schuler nor the Trust has effected any transactions in the Shares during the 60 days prior to the date hereof."
(d)	This Amendment hereby amends and restates Item 5(d) in its entirety as follows: "The Trust has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by it and the Shares that it has the right to acquire upon the exercise of 2022 Warrants, January 2024 Warrants, February 2025 Warrants and September 2025 Warrants. Mr. Schuler is the sole trustee of the Trust."
(e)	This Amendment hereby amends and restates Item 5(d) in its entirety as follows: "Not applicable."
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	This Amendment hereby amends and supplements Item 6 by adding the following thereto: "The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6. September 2025 Purchase Agreement and Common Stock and September 2025 Warrant On September 16, 2025, the Trust entered into a Securities Purchase Agreement, dated as of such date, among the Issuer, the Trust, and the other purchasers party thereto (the "September 2025 Purchase Agreement"), pursuant to which the Trust purchased from the Issuer the Common Stock and September 2025 Warrant (as defined below). The September 2025 Purchase Agreement contained customary terms and conditions. The foregoing description of the September 2025 Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 16, which exhibit is hereby incorporated herein by reference. On September 16, 2025, pursuant to the September 2025 Purchase Agreement, the Trust purchased from the Issuer 1,111,111 shares of Common Stock (the "Common Stock") and a warrant to purchase 833,333 shares of Common Stock (the "September 2025 Warrant"). The September 2025 Warrant is exercisable at $0.75 per share for five (5) years from the date of issuance. The foregoing description of the September 2025 Warrant does not purport to be complete and is qualified in its entirety by reference to the form thereof attached hereto as Exhibit 17, which exhibit is hereby incorporated herein by reference."
Item 7.	Material to be Filed as Exhibits.
	This Amendment hereby amends and supplements Item 7 by adding the following thereto: "There is filed herewith as Exhibit 16 the form of September 2025 Purchase Agreement. There is filed herewith as Exhibit 17 the form of September 2025 Warrant."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SCHULER JACK W

Signature:	/s/ Jack W Schuler
Name/Title:	Jack W. Schuler
Date:	09/18/2025

Jack W. Schuler Living Trust

Signature:	/s/ Jack W Schuler
Name/Title:	Jack W Schuler, Sole Trustee
Date:	09/18/2025

FAQ

What stake in Aspira Women's Health (AWHL) does Jack W. Schuler now hold?

The filing reports an aggregate beneficial ownership of 3,830,365 shares, equal to 9.1% of common stock on a 42,205,918 share basis.

What exactly did the Jack W. Schuler Living Trust purchase on September 16-17, 2025?

The Trust purchased 1,111,111 shares of common stock and received a warrant to purchase 833,333 shares pursuant to the September 2025 Purchase Agreement.

What are the terms of the September 2025 Warrant disclosed in the filing?

The September 2025 Warrant is exercisable at $0.75 per share and is exercisable for five years from issuance.

Does Mr. Schuler control the Trust's voting rights?

Yes. The filing states that Mr. Schuler is the sole trustee and the Trust holds shared voting power over 3,823,829 shares.

Were there any transactions in the 60 days prior to this amendment?

The filing states that neither Mr. Schuler nor the Trust effected any transactions in the Shares during the 60 days prior to the date of the amendment.